Sign in
CompletedPhase 2

Efficacy, Safety, and PK of M5717 in Combination With Pyronaridine as Chemoprevention in Adults and Adolescents With Asymptomatic Plasmodium Falciparum Infection (CAPTURE-2)

Key facts

Who runs it
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Where
Burkina Faso, Gambia, Kenya, and Zambia4 sites in 4 countriesChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 2
People taking part
192 people enrolled
Started
28 Nov 2023
Ended
29 Dec 2024
Type of study
Interventional, 4 groups
Treatments tested
  • M5717 60 mg
  • Pyronaridine
  • Atovaquone-Proguanil
  • M5717 200 mg
  • M5717 660mg
Record updated
6 February 2026

Who can take part

Age
12 years to 55 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (10)Hide the full registry criteria

Who can take part

  • Participants with Asymptomatic Plasmodium falciparum Malaria with no Fever or other sign of Acute Uncomplicated Malaria and, with Microscopic confirmation using Giemsa-stained thick film, and a Parasitemia of >= 40 to <= 10,000 Asexual Parasites/Microliter (μL) of Blood
  • Axillary Temperature < 37.0 degree Celcius (ºC) or oral/Tympanic/rectal Temperature< 37.5ºC; without history of fever during the previous 48 hours
  • Have a body weight >= 45 kilogram (kg)
  • Participants capable of giving Signed Informed consent which includes Compliance with the requirements and restriction listed in the Informed consent form
  • Other Protocol defined Inclusion Criteria could apply

Who cannot take part

  • Participants with any Preplanned surgery during the study
  • Participants with any previous Treatment with pyronaridine as part of a combination therapy during the last 3 months
  • Participants with any disease requiring Chronic Treatment
  • Participants with any adequate Hematological, Hepatic, and renal function as defined in the Protocol
  • Other protocol defined Exclusion Criteria could apply

Where is this trial?

It has sites in 4 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study evaluates the efficacy and safety of a single dose of M5717 plus pyronaridine tetraphosphate in clearing current Plasmodium falciparum infection and protecting against recurrent infections in asymptomatic adults and adolescents. The study will also assess the duration of protection provided by different doses of M5717 plus pyronaridine and the additional contribution of M5717 to the duration of protection using external study data.

The 4 groups in the trial

  • Cohort 1: M5717 (60 mg) + PyronaridineTreatment being tested

    Participants received single oral dose of M5717 60 milligram (mg) plus pyronaridine tetraphosphate (pyronaridine) 720 mg (Participants \>= 65 kilogram \[kg\]) or pyronaridine 540 mg (Participants \>= 45 to \< 65 kg) once daily in a single day treatment regimen.

    Treatment: M5717 60 mg and Pyronaridine

  • Cohort 2: M5717 (200 mg) + PyronaridineTreatment being tested

    Participants received single oral dose of M5717 200 mg plus pyronaridine 720 mg (Participants \>= 65 kg) or pyronaridine 540 mg (Participants \>= 45 to \< 65 kg) once daily in a single day treatment regimen.

    Treatment: Pyronaridine and M5717 200 mg

  • Cohort 3: M5717 (660 mg)+ PyronaridineTreatment being tested

    Participants received single oral dose of M5717 660 mg plus pyronaridine 720 mg (Participants \>= 65 kg) or pyronaridine 540 mg (Participants \>= 45 to \< 65 kg) once daily in a single day treatment regimen.

    Treatment: Pyronaridine and M5717 660mg

  • Cohort 4: Atovaquone-proguanilTreatment being tested

    Participants received orally 3 doses of Malarone (fixed-dose combination of atovaquone-proguanil) once daily in a 3-day treatment regimen.

    Treatment: Atovaquone-Proguanil

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Phase 2a Proof-of-Concept, Multicenter, Randomized, Open Label Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of a Single Dose of the Combination M5717-pyronaridine as Chemoprevention in Asymptomatic Adults and Adolescents With Plasmodium Falciparum Malaria Infection (CAPTURE-2)
Record updated
6 February 2026